Captopril

DRUG NAME: CAPTOPRIL

---

Therapeutic Class: Antihypertensive

---

Subclass: Angiotensin-Converting Enzyme Inhibitor (ACEi)

---

Schedule (India): Schedule H

---

Route(s)

• Oral (tablets — primary labelled route)
• Sublingual (off-label; widely practised in Indian emergency departments for hypertensive urgency — see Secondary Indications, Part 2)

• IV / IM / SC: No parenteral formulation of captopril exists or has ever been manufactured. When parenteral ACE inhibition is required (e.g., acute hypertensive emergency with impaired GI absorption), IV enalaprilat (the active diacid metabolite of enalapril) is the available injectable ACEi option.
• Topical / Inhaled / Rectal: No therapeutic rationale; no formulations exist.

---

Biosimilar Status:

---

Formulations Available in India

---

PHARMACOKINETICS

---

---

---

• Duration of adequate ACE inhibition relative to the dosing interval
• Captopril’s parent compound t½ of 2–3 hours means that ACE inhibition begins to wane by 6–8 hours post-dose, even though active disulfide metabolites provide residual activity
• For 24-hour ACE inhibition (critical in heart failure and chronic hypertension), TDS dosing is required
• For acute single-dose use (e.g., captopril challenge test, acute hypertensive urgency), the short duration is actually advantageous — effects wear off predictably, reducing the risk of prolonged hypotension

---

---

---

1. Free radical scavenging: The –SH group directly neutralises superoxide anion (O₂⁻) and other reactive oxygen species, providing antioxidant activity independent of the renin–angiotensin system
2. Nitric oxide (NO) potentiation: By reducing superoxide-mediated degradation of NO, captopril may enhance NO bioavailability and improve endothelial function
3. Disulfide bond formation: The thiol group reacts with endogenous thiols (cysteine, glutathione), forming mixed disulfides that may have independent biological properties — including S-nitrosothiol formation, which can serve as a NO donor

• Dysgeusia (taste disturbance) — incidence 2–4% (vs. <1% with other ACEis)
• Membranous nephropathy / proteinuria — principally at doses >150 mg/day
• Neutropenia / agranulocytosis — especially in patients with autoimmune connective tissue disease or renal impairment (incidence ~3.7 per 1,000 in high-risk groups)
• Pemphigus-like skin eruptions — rare but well-documented

---

---

ADULT INDICATIONS + DOSING

---

• ⚠️ In heart failure patients, abrupt cessation of ACEi can lead to haemodynamic deterioration (rising afterload, worsening neurohormonal activation) within days. Do not discontinue captopril abruptly in HF unless switching to another RAS blocker.
• If permanent discontinuation is required (e.g., refractory hyperkalaemia, AKI, angioedema), no taper is needed — the drug can be stopped immediately. Monitor BP and clinical status closely.

---

PRIMARY INDICATION 1: HYPERTENSION

---

• Inpatient BP titration where rapid onset (15–30 min) and short duration (6–12 hours) allow frequent dose adjustments — e.g., perioperative hypertension management, post-stroke BP optimisation, initial ACEi titration in hospitalised patients
• Significant hepatic impairment (Child-Pugh C) where prodrug ACEis (enalapril → enalaprilat; ramipril → ramiprilat) may have unpredictable activation — captopril, not being a prodrug, bypasses hepatic activation entirely
• When a very low ACEi test dose is needed (6.25 mg) to assess tolerability — easier to quarter a 25 mg scored tablet than to achieve equivalent low doses with some ACEi formulations

• Ramipril (5–10 mg OD; NLEM-listed): OD dosing, HOPE trial evidence — preferred for chronic outpatient use
• Enalapril (5–20 mg OD–BD; NLEM-listed): OD–BD dosing, IV enalaprilat available — preferred when parenteral ACEi may be needed
• Telmisartan (20–80 mg OD): OD dosing, no cough risk, widely available — preferred ARB alternative when ACEi cough is anticipated or intolerable
• Amlodipine (2.5–10 mg OD; NLEM-listed): No K⁺/creatinine monitoring — preferred when adherence or monitoring is a concern

• ⛔ Chronic outpatient hypertension in patients with adherence challenges (TDS dosing + empty stomach requirement = very poor adherence)
• ⛔ Patients unable to avoid food at dosing times (e.g., diabetic patients requiring frequent meals)
• ⛔ When reliable supply cannot be assured (limited market availability in India)
• ⛔ As a first-line antihypertensive when longer-acting, NLEM-listed alternatives (ramipril, enalapril, amlodipine) are available

• Single dose: BP reduction begins within 15–30 minutes, peaks at 60–90 minutes
• Steady-state antihypertensive effect: 1–2 weeks of regular dosing
• Full therapeutic response (at target dose): 4–6 weeks

• Failure to achieve target BP after 4–6 weeks at maximum tolerated dose (50 mg TDS) with confirmed adherence and dietary sodium restriction
• Intolerable ACEi-class adverse effects (cough — 5–20% in Indian population; angioedema — <1%)
• Persistent hyperkalaemia (K⁺ >5.5 mEq/L) despite dietary K⁺ restriction and removal of other K⁺-raising agents
• Switching options: Switch to ARB (telmisartan, losartan) if ACEi cough; add CCB or thiazide as combination if inadequate BP control

• ✅ Can be initiated in primary care for uncomplicated hypertension
• ⚠️ Specialist initiation recommended if: eGFR <30 mL/min, K⁺ >5.0 mEq/L, bilateral renal artery stenosis suspected, pregnancy risk, concurrent immunosuppressants

• Indian Guidelines on Hypertension IV (IGH-IV, 2019 — CSI/HSI/RSSDI joint guideline): ACEi is recommended as first-line antihypertensive, individually or in combination. Captopril is listed but no specific preference over other ACEis for chronic use.
• API Textbook of Medicine (10th edition): ACEi recommended for hypertension with compelling indications (diabetes, CKD, HF, post-MI).

• ⚠️ First-dose hypotension: Risk is LOW in uncomplicated hypertension but increases significantly with concurrent diuretic therapy, sodium restriction, or volume depletion. If patient is on a diuretic, consider reducing or withholding the diuretic 2–3 days before initiating captopril, or start at 6.25 mg under observation.
• ⚠️ Acute kidney injury: Monitor creatinine 1–2 weeks after initiation or dose increase. A creatinine rise of up to 30% from baseline is acceptable and expected (reflects reduced intraglomerular pressure — a desired haemodynamic effect). Rise >30% or absolute creatinine >3.5 mg/dL: withhold drug, investigate for bilateral renal artery stenosis, reassess.

• Concurrent diuretic: start at half the usual starting dose (6.25–12.5 mg)
• Elderly: start at 6.25–12.5 mg TDS; titrate slowly
• Renal impairment: see Renal Adjustment (Part 3)
• No adjustment needed for isolated hepatic impairment

---

BP Target Guidance (Antihypertensive Class-Specific):

• Recommended for all hypertensive patients where available
• Instruct: seated, rested for 5 minutes, same arm, twice daily (morning before medication and evening), average of 2 readings per sitting
• Home BP values are typically 5–10 mmHg lower than office readings
• If only home BP monitoring is available (e.g., rural/PHC settings), use home BP targets for decision-making

---

PRIMARY INDICATION 2: HEART FAILURE (HFrEF) / POST-MYOCARDIAL INFARCTION LEFT VENTRICULAR DYSFUNCTION

---

1. Place patient supine with legs elevated
2. Administer IV normal saline 250–500 mL bolus (unless pulmonary congestion present)
3. If SBP recovers to >90 mmHg and patient is asymptomatic: can re-attempt with same 6.25 mg dose next day, but continue diuretic dose reduction
4. If symptomatic hypotension persists: defer ACEi initiation; reassess volume status and diuretic dose

---

• ⛔ SBP persistently <90 mmHg despite volume optimisation
• ⛔ Bilateral renal artery stenosis (or unilateral in a single functioning kidney) — risk of acute renal failure
• ⛔ Serum K⁺ >5.5 mEq/L
• ⛔ History of ACEi-induced angioedema
• ⛔ Pregnancy (any trimester)
• ⚠️ Severe aortic stenosis (risk of syncope from fixed cardiac output)

• Haemodynamic benefit (reduced afterload, improved cardiac output): within hours of first dose
• Symptomatic improvement (dyspnoea, exercise tolerance): 1–4 weeks at target dose
• Mortality and hospitalisation benefit: demonstrated at 3–6 months in landmark trials; benefit continues with long-term use

• Persistent NYHA class III–IV symptoms despite target-dose ACEi + beta-blocker + MRA + diuretic
• Progressive LV dysfunction or dilation on serial echocardiography
• ≥2 HF hospitalisations within 12 months despite GDMT optimisation
• Action: Ensure dose optimisation of all GDMT components. Consider adding ARNI (sacubitril/valsartan — switch FROM ACEi WITH 36-hour washout), SGLT2i (dapagliflozin, empagliflozin), ivabradine, or hydralazine + isosorbide dinitrate (particularly in patients intolerant to ACEi/ARB or in Afro-Caribbean populations)

• MANDATORY: 2D Echocardiography with LVEF assessment (to confirm HFrEF)
• MANDATORY: NT-proBNP or BNP (baseline for future comparison)
• RECOMMENDED: Chest X-ray
• RECOMMENDED: Serum sodium, serum magnesium
• RECOMMENDED: Complete blood count (baseline for neutrophil monitoring with captopril)

• Unable to reach target dose (50 mg TDS) due to hypotension: maintain the highest tolerated dose (any dose > zero provides some benefit vs. no ACEi)
• Concurrent MRA initiated: recheck K⁺ within 1 week
• SGLT2i initiated: may allow better ACEi tolerance (SGLT2i-mediated natriuresis reduces congestion)

---

• SBP ≥100 mmHg (some protocols accept ≥90 mmHg with specialist oversight)
• No ongoing cardiogenic shock or haemodynamically significant RV infarction
• No severe mitral regurgitation or VSD requiring surgical intervention

• Captopril’s rapid onset and short duration are advantageous in the immediate post-MI period (days 3–14) when haemodynamic status may fluctuate — if hypotension develops, the effect dissipates within hours
• Before discharge: convert to ramipril (AIRE target: 5 mg BD) or enalapril for chronic maintenance

---

PRIMARY INDICATION 3: DIABETIC NEPHROPATHY — TYPE 1 DIABETES MELLITUS

---

• Ramipril (5–10 mg OD): NLEM-listed; OD dosing; MICRO-HOPE renoprotection data — preferred for chronic use
• Enalapril (10–20 mg OD–BD): NLEM-listed; AIIMS protocol choice
• ARBs (losartan, irbesartan): RENAAL and IDNT trials specifically enrolled Type 2 diabetic nephropathy patients. For Type 1 DM specifically, ACEi evidence is stronger than ARB evidence.

• ⛔ Type 2 diabetic nephropathy: while often extrapolated, the original Lewis trial enrolled exclusively Type 1 DM patients. ARBs (losartan, irbesartan) have specific Type 2 DKD evidence. ACEi use in Type 2 DKD is standard practice but captopril has no specific advantage.
• ⛔ Non-diabetic proteinuric CKD: ramipril (REIN trial) has the landmark evidence for this indication.
• ⚠️ eGFR <15 mL/min: high risk of severe hyperkalaemia; use only under nephrologist supervision.

• Reduction in proteinuria: measurable within 1–3 months
• Stabilisation of eGFR decline: 6–12 months
• Long-term renoprotective benefit (reduced progression to ESRD): demonstrated over 3–4 years in Lewis trial

• Persistent UACR >300 mg/g or rising proteinuria despite maximum tolerated dose + BP at target
• eGFR decline >5 mL/min/year despite optimised therapy
• Action: Confirm adherence, sodium restriction (<5 g/day), and optimal glycaemic control (HbA1c <7%). Consider adding finerenone (non-steroidal MRA) if available, or SGLT2i (dapagliflozin — DAPA-CKD; empagliflozin — EMPA-KIDNEY) for additional renoprotection.

• MANDATORY: Urine albumin-creatinine ratio (UACR) — quantitative baseline
• MANDATORY: eGFR
• MANDATORY: HbA1c
• RECOMMENDED: Fundoscopy (diabetic retinopathy often co-exists)

• eGFR 15–30: reduce starting dose to 6.25 mg TDS
• K⁺ 5.0–5.5: reduce dose; dietary K⁺ restriction; add K⁺-binding resin if needed
• K⁺ >5.5 persistently: discontinue ACEi; consider ARB with close monitoring, or hydralazine + isosorbide dinitrate as antihypertensive alternative

---

SECONDARY INDICATIONS — Adults Only (Off-label)

---

SECONDARY INDICATION 1: HYPERTENSIVE URGENCY (Oral) — OFF-LABEL but accepted standard practice in India

• No significant difference in Tmax, Cmax, or AUC between sublingual and oral captopril
• Captopril is NOT absorbed through the sublingual mucosa in clinically meaningful quantities
• The drug placed under the tongue dissolves in saliva, is swallowed, and follows the standard oral absorption pathway
• The perceived ”faster onset“ is attributable to the fasting-state rapid oral absorption (Tmax ~30–60 minutes) which occurs regardless of whether the tablet was placed under the tongue or swallowed

---

SECONDARY INDICATION 2: CAPTOPRIL CHALLENGE TEST / CAPTOPRIL RENOGRAPHY — Diagnostic Use

---

SECONDARY INDICATION 3: SCLERODERMA RENAL CRISIS

• Rapid onset (15–30 minutes) allows frequent dose titration in this acute crisis
• Short duration permits safe aggressive dose escalation over hours
• Steen et al. (Ann Intern Med 1990) used captopril as the primary ACEi in the landmark observational study demonstrating improved survival in SRC (1-year survival improved from ~15% to ~76% with ACEi)
• Other ACEis (enalapril, ramipril) are considered acceptable alternatives (class effect assumed), but captopril’s pharmacokinetic profile is uniquely suited to this rapid-titration scenario

---

MISSED DOSE / DELAYED DOSE GUIDANCE

Prolonged non-adherence / drug holiday guidance:

• ACEi class: No rebound hypertension risk upon discontinuation.
• If captopril was stopped for >1 week in a heart failure patient: Restart at 6.25–12.5 mg TDS and re-titrate over 1–2 weeks. Direct resumption at previous full dose risks first-dose hypotension (RAS reactivation during the drug holiday increases sensitivity to the first re-dose).
• If stopped for >1 month (any indication): Re-check creatinine, K⁺, and BP before restarting. Restart at initial starting dose.
• No immunogenicity concerns (not a biologic).
• No withdrawal syndrome.

---

RECONSTITUTION / ADMINISTRATION QUICK REFERENCE (For Nurses & Clinical Staff)

---

1. Crush the captopril tablet to a fine powder
2. Dissolve in 15–30 mL of purified water
3. Administer via NGT immediately after preparation
4. Flush the tube with 15–30 mL water after administration
5. ⚠️ Administer on empty stomach — hold tube feeds for 1 hour before and 30 minutes after captopril administration for optimal absorption

---

---

---

PAEDIATRIC DOSING (Specialist Only)

---

---

Neonatal Dosing

• Premature neonates (28–36 weeks): GFR is ~15–25 mL/min/1.73 m² and matures rapidly over the first 2 weeks. Captopril clearance is correspondingly reduced. Use the lowest starting dose and the longest dosing interval (every 12 hours). Recheck creatinine and K⁺ at 48 hours after initiation.
• Term neonates: GFR is ~25–40 mL/min/1.73 m² at birth, reaching ~60 mL/min/1.73 m² by 2 weeks. Can tolerate slightly higher mg/kg doses. Every-8-hour dosing is usually appropriate from day 3–5 of therapy.

• Oliguria / acute renal failure: Neonates are highly dependent on angiotensin II for maintaining GFR (afferent > efferent arteriolar tone). ACEi can cause oliguric renal failure in neonates, especially those who are volume-depleted, on concurrent nephrotoxic drugs (aminoglycosides, indomethacin), or have underlying renal anomalies.
• Severe hypotension: Even at the lowest doses.
• Hyperkalaemia: Common due to low GFR and limited renal K⁺ excretion capacity in neonates.
• Bone marrow effects: Exaggerated due to active haematopoiesis.

---

Primary Indications — Paediatric (Approved / Standard in India)

---

PAEDIATRIC PRIMARY INDICATION 1: HYPERTENSION

---

• Inpatient rapid dose titration is needed (e.g., post-cardiac surgery, neonatal hypertension, hypertensive crisis in children with acute glomerulonephritis or haemolytic uraemic syndrome)
• Very small infants/neonates where the extemporaneous oral solution provides precise, small-volume dosing
• When hepatic impairment precludes reliable activation of prodrug ACEis

• ⛔ Any trimester of pregnancy in an adolescent female
• ⛔ Bilateral renal artery stenosis
• ⛔ History of ACEi-induced angioedema
• ⚠️ Chronic outpatient use when TDS adherence is unlikely (poor compliance in school-going children)

• Acute: BP reduction within 15–30 minutes (faster in young children/infants with more active RAS)
• Chronic: 1–2 weeks for steady-state BP effect

• Failure to achieve age/height-appropriate BP target after 4 weeks at maximum tolerated dose
• ⚠️ In paediatric hypertension, always investigate for secondary causes (renal parenchymal disease, renal artery stenosis, coarctation, endocrine causes) — especially in children <6 years or with severe/resistant hypertension

• MANDATORY: Serum creatinine, eGFR, serum potassium
• MANDATORY: Urinalysis (proteinuria, haematuria — for underlying renal disease)
• RECOMMENDED: Renal ultrasound with Doppler (to exclude renal/renovascular causes)
• RECOMMENDED: Echocardiography (LVH assessment in sustained hypertension)
• RECOMMENDED in adolescent females: Pregnancy test (⛔ ACEi teratogenic)

• Concurrent diuretic: reduce starting dose by 50%
• Renal impairment: reduce dose — see Renal Adjustment section
• Neonates vs older children: see age-specific dosing table

---

PAEDIATRIC PRIMARY INDICATION 2: HEART FAILURE (HFrEF) — Paediatric

• When to prefer captopril: Short-acting profile useful in post-operative cardiac ICU for dose titration. In the PICU/NICU, captopril is often the first-choice oral ACEi because of rapid onset and predictable offset.
• Chronic outpatient paediatric HF: Enalapril (0.08–0.5 mg/kg/day, OD–BD) is preferred for adherence. IAP protocols list both captopril and enalapril as acceptable.
• Paediatric formulation advantage of captopril: Despite adherence disadvantage of TDS dosing, captopril’s advantage for neonates and young infants is that the extemporaneous solution allows precise small-dose titration — enalapril tablets are harder to crush into reliably accurate small doses.
• Monitoring in paediatric HF: Weight gain (assess growth), fluid intake, feeding tolerance (infants), exercise tolerance (older children), serum creatinine, potassium, echocardiographic LVEF.

---

Secondary Indications — Paediatric (Off-label, if any)

---

PAEDIATRIC SECONDARY INDICATION 1: PROTEINURIC RENAL DISEASE (Non-Diabetic) — OFF-LABEL

---

PAEDIATRIC SECONDARY INDICATION 2: BARTTER SYNDROME — OFF-LABEL

---

RENAL ADJUSTMENT

---

• Hypotension (excessive BP lowering)
• Hyperkalaemia (both from drug accumulation AND from disease-related impaired K⁺ excretion)
• Acute kidney injury (further reduction of intraglomerular pressure in kidneys dependent on angiotensin II for GFR maintenance)

---

---

---

• Captopril is available ONLY as immediate-release (IR) tablets. No modified-release (MR/ER/CR) formulation exists. Therefore, no MR formulation switching guidance is applicable.
• For patients unable to swallow tablets in CKD: extemporaneous 1 mg/mL solution (Part 2) or tablet crushing with water for NGT administration.

---

• In young, non-elderly ICU patients with augmented renal clearance (CrCl >130 mL/min — common in sepsis, trauma, burns), captopril would theoretically be cleared faster, potentially requiring shorter dosing intervals (every 6 hours instead of every 8 hours).
• However, captopril is rarely the ACEi of choice in ICU settings where oral absorption is unreliable. IV enalaprilat is preferred when parenteral ACEi is needed.
• If oral captopril IS used in a young ICU patient with ARC and inadequate BP response despite standard TDS dosing, consider switching to QID dosing or using a longer-acting ACEi (enalapril, ramipril) to maintain 24-hour ACE inhibition.

---

---

HEPATIC ADJUSTMENT

---

• The S-methyl metabolite is inactive (no ACE inhibitory activity)
• The primary active disulfide metabolites are formed systemically, not hepatically
• Elimination is 95% renal, not hepatic

---

---

However, if captopril is prescribed to a patient concurrently receiving known hepatotoxic drugs commonly used in Indian practice:

---

• Only immediate-release (IR) captopril tablets are available. No MR/ER/CR formulation exists.
• Therefore, formulation switching guidance is not applicable.

---

CONTRAINDICATIONS

---

Absolute Contraindications — Captopril Must NEVER Be Used:

---

Allergy and Cross-Reactivity — ACEi Class:

---

💡 Captopril-specific sulfhydryl ADRs vs ACEi class ADRs — distinguishing guide:

---

CAUTIONS

---

⚠️ HIGH-PRIORITY CAUTIONS:

---

Standard Cautions:

---

• Hypertension (uncomplicated): Low risk. Start 25 mg.
• Heart failure / diuretic-treated / volume-depleted: ⚠️ HIGH risk. Start 6.25 mg test dose under observation.
• Post-MI: Moderate risk. Start 6.25 mg after haemodynamic stability confirmed.

• ⚠️ Recommended at baseline and at each follow-up visit, especially in:
  • Elderly (≥60 years)
  • Diabetic patients (autonomic neuropathy)
  • Patients on concurrent vasodilators or diuretics
• Technique: Measure BP supine (after 5 minutes rest) and standing (at 1 and 3 minutes). Orthostatic hypotension = SBP drop ≥20 mmHg or DBP drop ≥10 mmHg, or symptoms on standing.
• If orthostatic hypotension documented: reduce captopril dose or reassess concurrent medications.

---

PREGNANCY

---

---

---

---

• Fetal ultrasound: amniotic fluid index, fetal renal structure, skull ossification, growth parameters
• Neonatal monitoring (if delivered after exposure): renal function, BP, serum K⁺, urine output

---

• Female fertility: No known direct effect on female fertility.
• Male fertility: No known clinically significant effect on male fertility at therapeutic doses. No washout period required before planned conception in males.

---

LACTATION

---

---

ELDERLY

---

---

---

Beers Criteria / STOPP-START Relevance:

• ACE inhibitors are NOT listed on the Beers Criteria as potentially inappropriate medications in the elderly. In fact, ACEis are a START criterion (drugs that SHOULD be prescribed in the elderly when indicated — specifically for HFrEF, post-MI, diabetic nephropathy, hypertension with CKD).
• STOPP criterion for captopril specifically: None specific to captopril. General STOPP criterion for ACEi: avoid in severe bilateral renal artery stenosis.

---

---

---

MAJOR DRUG INTERACTIONS

---

---

---

---

MODERATE DRUG INTERACTIONS

---

---

COMMON ADVERSE EFFECTS

---

---

SERIOUS ADVERSE EFFECTS

---

---

---

---

---

LABORATORY TEST INTERFERENCE

---

---

MONITORING REQUIREMENTS

---

A. BASELINE — Before Starting Captopril

---

MANDATORY Investigations (Drug must NOT be started without these)

---

• Establishes baseline renal function
• Identifies patients needing dose adjustment
• Identifies occult CKD
• If eGFR <30: specialist referral before starting

---

• K⁺ >5.5 mEq/L: ⛔ do NOT start ACEi until corrected
• K⁺ 5.0–5.5 mEq/L: start with caution at low dose; recheck in 3–5 days

---

• Record seated BP (average of 2 readings, 2 minutes apart, after 5 minutes rest)
• In elderly (≥60 years) and diabetic patients: check orthostatic BP (supine → standing at 1 and 3 minutes)
• Document baseline SBP:
  • SBP <90 mmHg → ⛔ do NOT start
  • SBP 90–100 mmHg → specialist initiation only

---

• ⛔ ACEi is teratogenic in all trimesters
• Urine pregnancy test (UPT) before initiation
• Document contraception plan in medical records

---

• Confirms HFrEF (LVEF ≤40%)
• NOT needed for uncomplicated hypertension

---

RECOMMENDED Investigations (Should be done; drug can be started while awaiting results if clinically urgent)

---

• Establishes baseline proteinuria
• Identifies diabetic nephropathy or occult renal disease
• Essential for monitoring renoprotective efficacy over time

---

• Identifies diabetes — a compelling indication for ACEi
• Diabetes is also a risk factor for hyperkalaemia on ACEi

---

• Hyponatraemia (<130 mEq/L) is a strong predictor of first-dose hypotension
• Important baseline for patients on concurrent diuretics

---

• ⚠️ Becomes MANDATORY (not just recommended) if patient has:
  • Autoimmune connective tissue disease (SLE, scleroderma, RA), AND/OR
  • eGFR <30 mL/min, AND/OR
  • Concurrent immunosuppressants (azathioprine, mycophenolate, cyclophosphamide)
• In general population: baseline CBC is prudent but not strictly mandatory (captopril-specific neutropenia incidence ~0.02%)
• In high-risk groups above: mandatory (incidence rises to ~0.37%)

---

• LVH assessment (hypertension)
• Baseline QTc documentation (not affected by captopril, but important for co-prescribed drugs)
• Exclude pre-existing conduction disease

---

• Baseline for future comparison
• Useful for detecting decompensation (>50% rise from stable baseline suggests worsening HF)
• NOT required to initiate ACEi in HF

---

OPTIONAL BUT HELPFUL Investigations

---

• Overall cardiovascular risk assessment
• Not required to start ACEi; obtain when convenient (e.g., at annual health check)

---

B. AFTER INITIATION / DOSE CHANGE

---

---

C. LONG-TERM / MAINTENANCE MONITORING

---

---

D. THERAPEUTIC DRUG MONITORING (TDM)

---

E. WHEN TO STOP MONITORING

• Monitoring should never be completely stopped for patients on long-term ACEi therapy.
• Monitoring frequency can be relaxed (e.g., annual creatinine and K⁺ instead of 3–6 monthly) ONLY if ALL of the following are met:
  • Stable on the same dose for ≥12 months
  • eGFR stable (≤10% variation over 12 months)
  • K⁺ consistently ≤5.0 mEq/L
  • No new interacting drugs added
  • No intercurrent illness affecting renal function

• Dose is changed
• New potentially interacting drug added (NSAID, K⁺-sparing diuretic, trimethoprim)
• Intercurrent illness (diarrhoea, vomiting, fever, dehydration)
• Surgery planned
• New diuretic started or diuretic dose changed

---

F. COMMON INVESTIGATION MISCONCEPTION FLAGS

---

---

PATIENT COUNSELLING

---

---

---

---

---

---

---

---

---

---

---

• Recognising signs of excessive BP lowering: sudden dizziness, fainting, confusion, reduced urine output → lie patient down, elevate legs, call doctor
• Recognising signs of angioedema: swelling of face/lips/tongue → MEDICAL EMERGENCY → rush to hospital
• Ensuring medication is taken on an empty stomach at consistent times
• Monitoring daily weight (heart failure patients) — sudden weight gain >1 kg/day suggests fluid retention → contact doctor
• Ensuring regular blood tests (creatinine, potassium) are completed even when patient feels well
• Not substituting ”lite salt“ or ”low sodium salt“ — explain why

---

---

BRANDS AVAILABLE IN INDIA

---

---

1. Verify local stocking before writing a captopril prescription
2. For chronic use: strongly consider switching to enalapril (widely available; NLEM) or ramipril (widely available; NLEM) at equivalent doses
3. For acute inpatient use: hospital pharmacy departments may need to procure captopril via special order or maintain limited stock for specific indications (scleroderma renal crisis, inpatient HF titration, hypertensive urgency)

---

PRICE RANGE (INR)

---

---

---

CLINICAL PEARLS

---

---

---

---

1. Confirm the cough is ACEi-related (dry, non-productive, worse at night, started weeks–months after ACEi initiation)
2. Rule out other causes (GERD, post-nasal drip, asthma, TB)
3. If truly ACEi-related and intolerable → switch to ARB (telmisartan, losartan) — cough incidence with ARBs is 1–2% (similar to placebo)
4. Do NOT switch to another ACEi — cough is a class effect and will recur

---

---

---

VERSION

---

---

REFERENCES

---

1. CDSCO product insert — Captopril tablets (Historical reference: Capoten, Cipla — licensee of Bristol-Myers Squibb; product insert revision ~2005). Used for: approved indications, contraindications, labelling information, adverse effects, dosing ranges. ℹ️ Captopril CDSCO-approved product insert is limited in availability due to declining market presence; data supplemented from international reference product insert (Capoten, BMS-USA — FDA-approved PI, revised 2012).
2. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th edition (2023). Editors: Brunton LL, Hilal-Dandan R, Knollmann BC. Chapter 28: ”Renin and Angiotensin“ — Captopril pharmacology, mechanism of action, sulfhydryl group properties, adverse effects, pharmacokinetics. Chapter 31: ”Antihypertensive agents and pharmacotherapy of hypertension.“ Used for: detailed pharmacology depth, PK parameters, mechanistic discussion of sulfhydryl-related ADRs, ACEi class effects, drug interactions.
3. Harrison’s Principles of Internal Medicine, 21st edition (2022). Editors: Loscalzo J, Fauci AS, Kasper DL, et al. Chapter 277: ”Hypertensive Vascular Disease“; Chapter 257: ”Heart Failure: Pathophysiology and Diagnosis“; Chapter 258: ”Heart Failure: Management.“ Used for: clinical context, BP targets, heart failure management principles, ACEi positioning in GDMT.
4. National List of Essential Medicines (NLEM), India 2022 — Ministry of Health & Family Welfare, Government of India. Used for: NLEM listing status of captopril (not listed) vs enalapril and ramipril (listed).
5. Indian Pharmacopoeia 2022 — Indian Pharmacopoeia Commission, Ghaziabad. Used for: pharmacopoeial standards reference. Captopril monograph included.

1. API Textbook of Medicine, 10th edition (2015). Association of Physicians of India. Editors: Shah SN, et al. Chapters on Hypertension, Heart Failure, Diabetic Nephropathy, Emergency Medicine. Used for: Indian clinical practice context, indication-specific clinical notes, treatment algorithms.
2. Indian Guidelines on Hypertension – IV (IGH-IV), 2019 — Cardiological Society of India (CSI), Hypertension Society of India (HSI), Research Society for Study of Diabetes in India (RSSDI). Journal of Human Hypertension 2020; 34: 745–758. Used for: BP targets, antihypertensive drug selection, combination therapy recommendations for Indian population.
3. RSSDI Clinical Practice Recommendations for Management of Type 2 Diabetes Mellitus, 2017 — Research Society for Study of Diabetes in India. Used for: ACEi/ARB recommendation in diabetic nephropathy.
4. CSI (Cardiological Society of India) Guidelines on Heart Failure Management — Indian Heart Journal (various years; most recent consensus ~2018). Used for: ACEi positioning in HFrEF in Indian practice.

1. IAP Textbook of Pediatrics, 6th edition (2016). Indian Academy of Pediatrics. Used for: paediatric dosing, neonatal hypertension management, paediatric heart failure.
2. IAP Guidelines on Evaluation and Management of Hypertension in Children and Adolescents — Indian Pediatrics 2014; 51: 379–397. Used for: paediatric hypertension BP targets, drug selection.
3. NNF (National Neonatology Forum) Protocol for Neonatal Hypertension — AIIMS, New Delhi. Used for: neonatal captopril dosing.

1. SAVE Trial: Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. N Engl J Med 1992; 327(10): 669–677. (n = 2,231)
2. Lewis Trial (Diabetic Nephropathy): Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329(20): 1456–1462. (n = 409)
3. ONTARGET Trial: Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358(15): 1547–1559. (n = 25,620) — Referenced for dual RAS blockade contraindication.
4. Scleroderma Renal Crisis (Steen et al.): Steen VD, Medsger TA Jr. Long-term outcomes of scleroderma renal crisis. Ann Intern Med 2000; 133(8): 600–603; and Steen VD, Costantino JP, Shapiro AP, Medsger TA Jr. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990; 113(5): 352–357.
5. Triple Whammy (Lapi et al.): Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ 2013; 346: e8525.
6. Sublingual Captopril PK (Angeli et al.): Angeli P, Chiesa M, Caregaro L, et al. Comparison of sublingual captopril and nifedipine in immediate treatment of hypertensive emergencies. A randomized, single-blind clinical trial. Arch Intern Med 1991; 151(4): 678–682; and related PK studies.

1. CDSCO Website (cdsco.gov.in) — used for: Schedule classification verification, NSQ alert review, banned FDC verification.
2. 1mg.com and PharmEasy.in — used for: current Indian brand availability verification, price verification, formulation strength confirmation. Accessed June–July 2025.
3. NPPA (National Pharmaceutical Pricing Authority) — nppa.nic.in — used for: DPCO price ceiling status verification.
4. ACE I/D Polymorphism in Indian Population: Narain R, Saxena A, Dwivedi SK, et al. ACE gene I/D polymorphism in North Indian population. Indian Heart J 2007; 59(6): 492–496. Used for: pharmacogenomic variant prevalence data.

---